Citations

Clear

3030 citation(s) found for "Susan, M".

BIOM-12. ALLIANCE A071401: GENOMICALLY GUIDED PHASE II TRIAL OF ABEMACICLIB IN PATIENTS WITH GRADE 2/3 MENINGIOMAS HARBORING SOMATIC NF2 OR CDK PATHWAY ALTERATIONS
Dooley, Katharine , Geyer, Susan M. , Gerstner, Elizabeth R. , Iafrate, A. John , Welch, Mary , Chan, Amy, Kumthekar, Priya , Matsuoka, Carlos Kamiya , Strowd, Roy, Cohen, Adam L. , Jaeckle, Kurt A. , Robell, Lindsay, Magge, Rajiv , Nam, Joo Yeon , Blondin, Nicholas, Shaikh, Nawal , Rabinowitz, Ian , Thomas, Alissa A. , Barker, Frederick G., Brastianos, Priscilla K. , Kaufmann, Timothy J. , Martinez‐Lage, Maria , Milhem, Mohammed , Kaley, Thomas , Drappatz, Jan , Cahill, Daniel P. , Santagata, Sandro , Galanis, Evanthia

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii21-viii21

10.1093/neuonc/noae165.0085 Get It

Abstract BACKGROUND Patients with meningiomas that have progressed after surgery and/or radiation have limited treatments. Loss of NF2 and CDKN2A/B are common in higher-grade meningiomas and promote meningioma progression. We evaluated the efficacy of abemaciclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, as part of Alliance A071401, a genomically-driven phase II trial in recurrent or progressive meningiomas. METHODS Eligible patients (pts) with grade 2/3 tumors and NF2 mutations or CDK pathway alterations were treated with abemaciclib 200 mg orally twice daily. Two co-primary endpoints were used: progression-free survival at 6 months (PFS6) and response rate (RR); the trial would be declared positive if either endpoint was met. Twenty-four evaluable pts provided ≥85% power to detect a PFS6 ≥41.5% (vs. null 15%; alpha=0.02), and ≥89% power to detect RR ≥20% (vs. null 2.5%; alpha=0.021). RESULTS Of 83 pts screened while the abemaciclib arm was open between September 15, 2021 and October 3, 2022, 36 eligible pts received abemaciclib. The observed PFS6 rate in the first 24 evaluable pts was 54% (95% CI 33-75%), thus the study met PFS6 endpoint. Of all 35 evaluable pts, median PFS was 7.6 months (95% CI 3.6-17.1 months), estimated 6-month PFS was 55% (95% CI 40-75%) and estimated 6-month OS was 88% (95% CI 77-100%). No objective responses were observed. Of the 36 pts who started treatment, two had a grade 4 adverse event at least possibly related to treatment which included ALT elevation(1), AST elevation(1) and vomiting(1). Patients with NF2 alterations (n=24) had favorable PFS6 outcomes (58%, 95% CI 37-78%) compared to those with CDK (n=4, 25%, 95% CI 1-81%) and CDK+NF2 alterations (n=7, 29% 95% CI 4-71%), (Fisher’s Exact p=0.036). CONCLUSIONS Abemaciclib was well-tolerated and resulted in improved PFS6, meeting the trial’s co-primary endpoint. Abemaciclib warrants further investigation for the treatment of patients with progressive meningiomas.
CTNI-56. PHASE I STUDY OF VORINOSTAT AND TEMSIROLIMUS IN NEWLY DIAGNOSED OR PROGRESSIVE DIFFUSE INTRINSIC PONTINE GLIOMA
Baig, Muhammad Usman , Mahajan, Anita , McGovern, Susan L. , Hertell, Leena M Von, Khatua, Soumen , Zaky, Wafik , Stitzlein, Lea , Baig, Muhammad Usman, Chandra, Joya , Paulino, Arnold C. , Andersen, Clark R. , Gill, Jonathan Benjamin

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii109-viii109

10.1093/neuonc/noae165.0423 Get It

Abstract BACKGROUND Diffuse intrinsic pontine glioma (DIPG) carries a poor prognosis with a median survival of less than 12 months. Histone mutation, K27M, and AKT pathway dysregulation play key roles in tumorigenesis. There is no curative treatment with radiation therapy, which currently remains the standard treatment. METHODS This is a phase I study of vorinostat and temsirolimus in newly diagnosed (stratum 1) and progressive (stratum 2) DIPG. The primary aims are to determine the safety, maximum tolerated dose, and toxicities (NCT02420613). Stratum 1 received radiation concurrently with vorinostat, followed by vorinostat and temsirolimus for up to 10 cycles. Stratum 2 received vorinostat and temsirolimus for up to 12 cycles. In stratum 1, vorinostat was administered daily at 230 mg/m2. The maintenance phase (both strata) included concurrent vorinostat 230 mg/m2 daily and temsirolimus 25 or 35 mg/m2 (Days 1 and 8). RESULTS Six patients were enrolled, three in each stratum. Three of the six patients had confirmed H3 K27M mutations. No dose-limiting toxicity was observed, and most adverse effects were limited to grades 1 or 2, including fatigue, nausea, vomiting, myelosuppression, hyperlipidemia, hyperglycemia, elevated liver enzymes, and creatinine. However, one patient experienced grade 3 leukopenia. Two of the three patients in stratum 1 showed evidence of radiographic response after the chemoradiation phase, of whom one patient had progression-free survival of 12 months and completed the 10 maintenance cycles. All patients at stratum 2 had disease progression with no radiographic response. CONCLUSION Overall, the combination of temsirolimus and vorinostat is well tolerated and safe, prompting the need for larger studies to investigate its efficacy. Due to the small number of patients, the study’s findings are limited, and trends in efficacy should be interpreted with caution.
PATH-30. CLINICAL OUTCOMES AND PREDICTIVE BIOMARKERS FOR IDH-WILDTYPE GLIOBLASTOMAS DEVELOPING HYPERMUTATION FOLLOWING TEMOZOLOMIDE TREATMENT
Al-Adli, Nadeem , Gupta, Rohit , Wu, Jasper, Ravindranathan, Ajay , Shai, Anny , Oberheim-Bush, Nancy Ann, Taylor, Jennie , Villanueva‐Meyer, Javier , Bollen, Andy, Theodosopoulos, Philip V. , Chang, Edward F. , Hervey‐Jumper, Shawn L. , Raleigh, David R. , Díaz, Aarón , Costello, J , Clarke, Jennifer , Butowski, Nicholas , Phillips, Joanna J. , Chang, Susan M. , Solomon, David, Young, Jacob S. , Lucas, Calixto‐Hope G. , Morshed, Ramin A. , Groot, John de , Villanueva-Meyer, Javier E. , Pekmezci, Melike , Perry, Arie , Aghi, Manish Kumar , Berger, Mitchel S.

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii185-viii185

10.1093/neuonc/noae165.0729 Get It

Abstract Current standard of care for IDH-wildtype glioblastoma (GBM) includes maximal safe resection, adjuvant radiation, and chemotherapy with the alkylating agent temozolomide. A subset of gliomas treated with temozolomide develop somatic hypermutation with a predominance of C>T transitions due to the alkylation effects on DNA. However, the frequency of occurrence, clinical ramifications, and predictive biomarkers for developing temozolomide-induced hypermutation (TMZ-HM) in GBM are unknown. Here we performed comprehensive histopathologic, genomic, and epigenomic evaluation of paired initial and recurrent GBM from 106 patients. Seven patients (7%) developed hypermutation at time of first recurrence, while an additional five patients (5%) developed hypermutation at a subsequent recurrence. Patients who developed TMZ-HM had a significantly longer interval between initial surgery and first recurrence (27.8 vs. 9.9 months, p<0.001). In contrast to IDH-mutant gliomas where TMZ-HM is associated with poor prognosis, those patients with IDH-wildtype GBM who developed TMZ-HM had significantly longer overall survival from both initial surgery (67.9 vs. 20.3 months, p<0.001) and from time of recurrence after development of hypermutation (30.9 vs. 9.5 months, p=0.001). There was no difference in oncogenic alteration frequency in initial GBM that subsequently developed TMZ-HM. However, 4 specific CpG sites out of 12 total interrogated sites in the promoter region of MGMT (a DNA repair enzyme) and 5 specific CpG sites in the promoter region of KCNQ1DN (a negative regulator of c-Myc) were significantly more hypermethylated in those GBM that developed TMZ-HM. We then generated a weighted risk score across these CpG sites that can be used to prospectively identify GBM likely to develop TMZ-HM associated with favorable survival. In summary, patients with GBM that develop TMZ-HM follow a more favorable clinical course, and specific MGMT and KCNQ1DN promoter hypermethylation patterns could serve as a biomarker to identify these patients who may potentially benefit from extended alkylating chemotherapy treatment.
Optimizing influenza vaccine allocation: A predictive analytics approach for informed public health planning
Flaker, Susan M, Holm, Michelle R., Gilmer, Mary, Perry, Adam, Martindale-Mathern, Sonia C., Holm, Michelle, Martindale-Mathern, Sonia, Perry, Adam

Mayo Clinic

American Journal of Health-System Pharmacy | November 9, 2024 | Volume: 82 | Issue: 10 | Pages: 544-550

10.1093/ajhp/zxae336 | PMID 39520176 Get It

Abstract Purpose Excessive purchasing of influenza vaccine can lead to costly overages and waste of resources. Insufficient quantities, however, can jeopardize population health. Our project aimed to use predictive analytics to determine the influenza vaccine quantities that would be needed for the next influenza season while minimizing vaccine waste and meeting patient care demands. Methods Several data sources were evaluated to develop a predictive analytics model to better estimate future influenza vaccine orders during upcoming influenza seasons. A retrospective analysis of influenza vaccine administrations over the last 4 influenza seasons allowed the team to develop an algorithm to predict influenza vaccine needs. Two regions within Mayo Clinic were selected to determine the validity of our ordering process. These 2 regions, identified as regions 3 and 5, ordered influenza vaccines based on the algorithm, while the other 3 regions acted as control groups, ordering though traditional methods based on purchasing data. Results Predictive analysis for the 2 intervention regions resulted in a savings of over $1 million when compared to traditional ordering methods. The model predicted that the quantity of vaccine ordered should be 17,574.16 and 9,164.29 quadrivalent influenza vaccines for regions 3 and 5, respectively. On the basis of actual administration data, 15,902 vaccines for region 3 and 9,016 vaccines for region 5 will be administered by the end of the season, both of which are less than the predicted amount needed, demonstrating the accuracy of the analytics. Conclusion Compared to the traditional ordering method, ordering using predictive analytics allowed the team to more accurately determine future order volumes and spend, yielding significant cost savings.
PRC with Double Interposition Arthroplasty for Failed Partial Wrist Arthrodesis
Cantwell, Susan, Kakar, Sanjeev , Cantwell, Sean R , Kakar, Sanjeev

Mayo Clinic

Journal of Wrist Surgery | November 8, 2024 | Volume: 15 | Issue: 01 | Pages: e29-e33

10.1055/s-0044-1791951 | PMID 41574165 Get It

Abstract In patients with lunate fossa and proximal capitate degeneration, or failed scaphoid excision and partial wrist arthrodesis, double allograft interposition arthroplasty may allow patients to maintain wrist motion and improve pain. Following dorsal exposure of the carpus, a completion proximal row carpectomy is performed. Suture anchors are placed evenly along the perimeter of the distal radius and used to secure a precut sheet of allograft. Additional suture anchors are placed at the proximal aspect of the distal carpal row, securing a second piece of allograft to the proximal capitate and hamate. We present the case of a female with osteogenesis imperfecta who failed prior partial wrist fusion for treatment of scapholunate advanced collapse. She declined wrist arthrodesis and was not a candidate for total wrist arthroplasty. Proximal row carpectomy with double interposition arthroplasty provided resolution of her pain and preserved her wrist range of motion. Double interposition arthroplasty may provide reliable pain relief and wrist range of motion for patients with advanced wrist arthritis in whom traditional salvage procedures are contraindicated or have failed. Use of this technique offers benefits that may minimize complications and improve longevity compared with previously described allograft interposition techniques.
Pathogenic Variants in Cancer Susceptibility Genes Predispose to Ductal Carcinoma In Situ of the Breast
Huang, Huaizhi , Couch, Ronan E. , Karam, Rachid , Boddicker, Nicholas , Polley, Eric C. , Na, Jie , Ambrosone, Christine B. , Yao, Song , Trentham‐Dietz, Amy , Bodelón, Clara , Hodge, James M. , Patel, Alpa V. , Haiman, Christopher A. , John, Esther M. , Vachon, Celine M. , Ruddy, Kathryn J. , Goldgar, David E. , Nathanson, Katherine L. , Weitzel, Jeffrey N. , Dolinsky, Jill S. , Pesaran, Tina , Hu, Chunling , Boddicker, Nicholas J , Polley, Eric C , Na, Jie , Ambrosone, Christine B , Yao, Song , Trentham-Dietz, Amy , Eliassen, A Heather , Penney, Kathryn , Brantley, Kristen D , Bodelon, Clara , Teras, Lauren R , Hodge, James M , Patel, Alpa V , Haiman, Christopher A , John, Esther M , Neuhausen, Susan L. , Martı́nez, Marı́a Elena , Lacey, James V. , O'Brien, Katie M , Sandler, Dale P , Weinberg, Clarice R , Palmer, Julie R , Bertrand, Kimberly A , Vachon, Celine M. , Olson, Janet E , Ruddy, Kathryn J , Anton-Culver, Hoda , Ziogas, Argyrios , Goldgar, David E , Nathanson, Katherine L , Domchek, Susan M , Weitzel, Jeffrey N , Kraft, Peter , Dolinsky, Jill S , Pesaran, Tina , Richardson, Marcy E , Yadav, Siddhartha , Couch, Fergus J. , Karam, Rachid , Huang, Huaizhi , Couch, Ronan , Hu, Chunling , Eliassen, A. Heather , Brantley, Kristen D. , Teras, Lauren R. , O’Brien, Katie M. , Sandler, Dale P. , Weinberg, Clarice R. , Palmer, Julie R. , Bertrand, Kimberly A. , Olson, Janet E. , Anton‐Culver, Hoda , Ziogas, Argyrios , Domchek, Susan M. , Kraft, Peter , Yadav, Siddhartha , Couch, Fergus J.

Mayo Clinic

Clinical Cancer Research | November 8, 2024 | Volume: 31 | Issue: 1 | Pages: 130-138

10.1158/1078-0432.ccr-24-1884 | PMID 39513960 Get It

Abstract Purpose: To determine the relationship between germline pathogenic variants (PV) in cancer predisposition genes and the risk of ductal carcinoma in situ (DCIS). Experimental Design: Germline PV frequencies in breast cancer predisposition genes (ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, RAD51C, and RAD51D) were compared between DCIS cases and unaffected controls and between DCIS and invasive ductal breast cancer (IDC) cases from a clinical testing cohort (n = 9,887), a population-based cohort (n = 3,876), and the UK Biobank (n = 2,421). The risk of contralateral breast cancer (CBC) for DCIS cases with PV was estimated in the population-based cohort. Results: Germline PV were observed in 6.5% and 4.6% of women with DCIS in the clinical testing and population-based cohorts, respectively. BRCA1, BRCA2, and PALB2 PV frequencies were significantly lower among women with DCIS than those with IDC (clinical cohort: 2.8% vs. 5.7%; population-based cohort: 1.7% vs. 3.7%), whereas the PV frequencies for ATM and CHEK2 were similar. ATM, BRCA1, BRCA2, CHEK2, and PALB2 PV were significantly associated with an increased risk of DCIS (OR > 2.0), but only BRCA2 PV were associated with high risk (OR > 4) in both cohorts. The cumulative incidence of CBC among carriers of PV in high-penetrance genes with DCIS was 23% over 15 years. Conclusions: The enrichment of PV in ATM, BRCA1, BRCA2, CHEK2, and PALB2 among women with DCIS suggests that multigene panel testing may be appropriate for women with DCIS. Elevated risks of CBC in carriers of PV in high-penetrance genes with DCIS confirmed the utility of testing for surgical decision-making.
Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study
Montagna, Giacomo , Laws, Alison , Ferrucci, Massimo , Mrdutt, Mary M., Sun, Susie X. , Bademler, Süleyman , Balbaloĝlu, Hakan , Balint‐Lahat, Nora, Banys-Paluchowski, Maggie, Barrio, Andrea V. , Benson, John R. , Beşe, Nuran , Boyle, Marissa K. , Diego, Emilia J. , Eden, Claire , Eller, Ruth S. , Goldschmidt, Maite, Hlavin, Callie , Heidinger, Martin , Jelinska, Justyna, Çakmak, Güldeniz Karadeniz , King, Tari A. , Kuerer, Henry M. , Loesch, Julie M, Milardi, Francesco , Murawa, Dawid , Moo, Tracy‐Ann , Menes, Tehillah S. , Passeri, Daniele , Pastoriza, Jessica , Perhavec, Andraž , Pislar, Nina , Polidorio, Natália , Rami, Avina , Ryu, Jai Min , Schulz, Alexandra , Sevilimedu, Varadan , Uğurlu, Mustafa Ümit , Uras, Cihan, Hemert, Annemiek K. E. van , Wong, Stephanie M. , Yoo, Tae-Kyung , Zhang, Jennifer Q. , Cabıoğlu, Neslihan , Peeters, Marie-Jeanne T. F. D. Vrancken , Morrow, Monica , Weber, William P. , Group, on behalf of the ICARO Study, Andreozzi, Mariacarla, Barbalho, Daniel Meirelles , Boileau, J.-F., Brogi, Edi , Cabero, Flávia Vidal, Cocco, Daniela , Bree, Eelco de , Vernet-Tomás, M. , Deutschmann, Christine , Ditsch, Nina, Fick, Franziska, Fitzal, Florian , Flanagan, Meghan R. , Gentile, Damiano , Grabenstetter, Anne , Heil, Jörg, Holtschmidt, Johannes , Krawczyk, Natalia , Kühn, Thorsten, Kümmel, Sherko, Muslumanoglu, Mahmut , Nekljudova, Valentina , Newman, Lisa A. , Poulakaki, Fiorita , Schwartz, Christopher J. , Siegel, Emily , Simonson, Colin , Tampaki, Ekaterini Christina , Tampakis, Athanasios , Tausch, Christoph, Bruele, Astrid Botty van den , Vorburger, Denise , Weiss, Anna, Wimmer, Kerstin , Woodward, Steven G. , Ziauddin, Firdos M., Boughey, JC , Boyle, Marissa K , Eller, Ruth , Heidinger, Martin , Karadeniz Cakmak, Güldeniz , Kesmodel, Susan B , King, Tari A , Milardi, Francesco , Murawa, Dawid , Menes, Tehillah S , Passeri, Daniele , Pastoriza, Jessica M , Perhavec, Andraz , Polidorio, Natália , Rami, Avina , Ugurlu, M Umit , van Hemert, Annemiek , Yoo, Tae-Kyung Robyn , Zhang, Jennifer Q , Peeters, Marie-Jeanne Vrancken , Morrow, Monica , Weber, Walter P , Wong, Stephanie M , Mrdutt, Mary M , Banys‐Paluchowski, Maggie , Boughey, Judy C. , Uras, Cihan , Karanlık, Hasan , Group, on behalf of the ICARO Study, Ahn, Sung Gwe , Corsi, Fabio , Crown, Angelena , Esposito, Emanuela , Fayanju, Oluwadamilola M. , Gentilini, Oreste D , Gülçelik, Mehmet Ali , Heil, Joerg , Leo, Cornelia , Pilewskie, Melissa , Riedel, Fabian , Rocco, Nicola , Schnabel, Freya Ruth , Singer, Christian F. , Soares, Leonardo Ribeiro , Tasoulis, Marios Konstantinos , Urban, Cicero A. , Vergauwen, Glenn , Wärnberg, Fredrik , Williams, Austin David

Mayo Clinic

Journal of Clinical Oncology | November 7, 2024 | Volume: 43 | Issue: 7 | Pages: 810-820

10.1200/jco.24.01052 | PMID 39509672 Get It

PURPOSE The nodal burden of patients with residual isolated tumor cells (ITCs) in the sentinel lymph nodes (SLNs) after neoadjuvant chemotherapy (NAC) (ypN0i+) is unknown, and axillary management is not standardized. We investigated rates of additional positive lymph nodes (LNs) at axillary lymph node dissection (ALND) and oncologic outcomes in patients with ypN0i+ treated with and without ALND. METHODS The Oncoplastic Breast Consortium-05/ICARO cohort study (ClinicalTrials.gov identifier: NCT06464341 ) retrospectively analyzed data from patients with stage I to III breast cancer with ITCs in SLNs after NAC from 62 centers in 18 countries. The primary end point was the 3-year rate of any axillary recurrence. The rate of any invasive recurrence was the secondary end point. RESULTS In total, 583 patients were included, of whom 182 (31%) had completion ALND and 401 (69%) did not. The median age was 48 years. Most patients (74%) were clinically node-positive at diagnosis and 41% had hormone receptor–positive/human epidermal growth factor receptor 2–negative tumors. The mean number of SLNs with ITCs was 1.2. Patients treated with ALND were more likely to present with cN2/3 disease (17% v 7%, P < .001), have ITCs detected on frozen section (62% v 8%, P < .001), have lymphovascular invasion (38% v 24%, P < .001), and receive adjuvant chest wall (89% v 78%, P = .024) and nodal radiation (82% v 75%, P = .038). Additional positive nodes were found at ALND in 30% of patients, but only 5% had macrometastases. The 3-year rates of any axillary and any invasive recurrence were 2% (95% CI, 0.95 to 3.6) and 11% (95% CI, 8 to 14), respectively, with no statistical difference by type of axillary surgery. CONCLUSION The nodal burden in patients with ypN0(i+) was low, and axillary recurrence after ALND omission was rare in patients selected for this approach. These results do not support routine ALND in all patients with ypN0(i+).
Interdisciplinary Operating Room Ergonomics Needs and Priorities
Mah, Alexis , Larouche, Jérémie , Dandal, Marie-Antonette, Cohen, Tara , Kallocsai, Csilla, Sriram, Sapna, Helman, James D., Hallet, Julie , Hallbeck, Susan, Norasi, Hamid , Hallet, Julie , Alam, Fahad , Hallbeck, M. Susan , Sriram, Sapna

Mayo Clinic

Annals of Surgery | November 6, 2024 | Volume: 283 | Issue: 5 | Pages: 769-775

10.1097/sla.0000000000006582 | PMID 39502068 Get It

Objective: To examine perceived operating room (OR) ergonomics facilitators and barriers, with a focus on the interdisciplinary team. Background: Poor ergonomics causes musculoskeletal injuries affecting all OR staff with repercussions on patient care, outcomes, and sustainability. Lack of ergonomic awareness and education are risk factors. Methods: We conducted a self-administered web-based survey of OR nurses, surgeons, and anesthesiologists at a single center (n = 238). We developed a questionnaire through item generation and reduction, followed by reliability and validity testing. Results: Response rate was 53.8%. Respondents perceived that on average 80% of nurses, 70% of surgeons, and 40% of anesthesiologists experienced musculoskeletal (MSK) injuries, with no difference in professional groups’ perceptions. Guideline ergonomics interventions were rarely used (<25%) except for specialized clothing (33%), equipment repositioning (59%), and seating (37%), though perceived as beneficial by 80% to 90%. Reported barriers to optimal ergonomics were organizational/structural (lack of time, space, equipment, funding), whereas solutions were individual. Fear of unfavorable perceptions from others was a concern for 62%. Teams discussing, prioritizing, monitoring, or helping with ergonomics was indicated by <50%. Individual ergonomic adaptations were perceived as convenience by other staff. Conclusions: While structural/organizational issues are reported as barriers to ergonomics, solutions appear as individual responsibilities. Team dynamics did not prioritize nor support ergonomics. Education tools leveraging the interdisciplinary team are warranted. This work will be supplemented by interviews and live observations to build tailored educational tools for OR teams.
Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer
Hamilton, Phineas T. , Phung, Minh Tung , Stevens, Donald L.I., Kalaria, Shreena , Laumont, Céline M. , Moss, Elena, Alimujiang, Aliya , Meagher, Nicola S. , Hendley, Joy , Goode, Ellen L. , Shen, Hui , Richardson, Jean , Deurloo, Cindy McKinnon, Chase, Anne, Grout, Bronwyn, Cushing‐Haugen, Kara L. , Anglesio, Michael S. , Huntsman, David G. , Talhouk, Aline , Hanley, Gillian E. , Alsop, Jennifer , Jimenez-Linan, Mercedes , Boros, Jessica , Brand, Alison H. , Sharma, Raghwa , Hecht, Jonathan L. , Sasamoto, Naoko , Terry, Kathryn L. , Lester, Jenny, Carney, Michael E. , Goodman, Marc T. , Fasching, Peter A., Bisinotto, Christiani, Le, Nhu D. , Menon, Usha , García, María J. , Rodríguez‐Antona, Cristina , Farrington, Kyo , Kelemen, Linda E. , Kommoss, Stefan , Staebler, Annette , Garsed, Dale W. , Piskorz, Anna , Bowtell, David D.L. , Ramus, Susan J. , Pike, Malcolm C., Pearce, Celeste Leigh , Ramus, Susan J , Rodríguez-Antona, Cristina , Menon, Usha , Anglesio, Michael S , Brand, Alison H , Bowtell, David D , Garsed, Dale W , Goodman, Marc T , Phung, Minh Tung , Nelson, Brad H. , Milne, Katy , Harris, Bronwyn, Thornton, Shelby , Singh, Karanvir , Bolithon, Adelyn , Fereday, Sián , Kennedy, Catherine J. , Ariyaratne, Dinuka , Alsop, Kathryn , Traficante, Nadia , Karnezis, Anthony N. , Chase, Anne, Doherty, Jennifer A. , Harris, Holly R. , Heinze, Karolin , Pharoah, Paul D.P. , Harnett, Paul R. , Karlan, Beth Y. , Hernandez, Brenda Y. , Wilkens, Lynne R. , Behrens, Sabine , Fortner, Renée T. , Reis, Francisco José Cândido dos , Ghatage, Prafull , Köbel, Martin , Elishaev, Esther , Modugno, Francesmary , Cook, Linda S. , Gentry‐Maharaj, Aleksandra , Brenton, James D. , DeFazio, Anna

Mayo Clinic

Journal of Clinical Investigation | October 29, 2024 | Volume: 134 | Issue: 24 | Pages: No page available

10.1172/jci179501 | PMID 39470729 Get It

BACKGROUND Despite an overall poor prognosis, about 15% of patients with advanced-stage tubo-ovarian high-grade serous carcinoma (HGSC) survive 10 or more years after standard treatment. METHODS We evaluated the tumor microenvironment of this exceptional, understudied group using a large international cohort enriched for long-term survivors (LTS; 10+ years; n = 374) compared with mid-term (MTS; 5–7.99 years; n = 433) and short-term survivors (STS; 2–4.99 years; n = 416). Primary tumor samples were immunostained and scored for intraepithelial and intrastromal densities of 10 immune-cell subsets (including T cells, B cells, plasma cells, myeloid cells, PD-1 + cells, and PD-L1 + cells) and epithelial content. RESULTS Positive associations with LTS compared with STS were seen for 9 of 10 immune-cell subsets. In particular, the combination of intraepithelial CD8 + T cells and intrastromal B cells showed near 5-fold increased odds of LTS compared with STS. All of these associations were stronger in tumors with high epithelial content and/or the C4/Differentiated molecular subtype, despite immune-cell densities generally being higher in tumors with low epithelial content and/or the C2/Immunoreactive molecular subtype. CONCLUSION The tumor microenvironment of HGSC LTS is distinguished by the intersection of T and B cell coinfiltration, high epithelial content, and C4/differentiated molecular subtype, features which may inspire new approaches to immunotherapy. FUNDING Ovarian Cancer Research Program (OCRP) of the Congressionally Directed Medical Research Program (CDMRP), U.S. Department of Defense (DOD); American Cancer Society; BC Cancer Foundation; Canada’s Networks of Centres of Excellence; Canadian Cancer Society; Canadian Institutes of Health Research; Cancer Councils of New South Wales, Victoria, Queensland, South Australia, and Tasmania, Cancer Foundation of Western Australia; Cancer Institute NSW; Cancer Research UK; Deutsche Forschungsgesellschaft; ELAN Funds of the University of Erlangen-Nuremberg; Fred C. and Katherine B. Andersen Foundation; Genome BC; German Cancer Research Center; German Federal Ministry of Education and Research, Programme of Clinical Biomedical Research; Instituto de Salud Carlos III; Mayo Foundation; Minnesota Ovarian Cancer Alliance; Ministerio de Economía y Competitividad; Medical Research Council (MRC); National Center for Advancing Translational Sciences; National Health and Medical Research Council of Australia (NHMRC); Ovarian Cancer Australia; Peter MacCallum Foundation; Sydney West Translational Cancer Research Centre; Terry Fox Research Institute; The Eve Appeal (The Oak Foundation); UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge; University of Pittsburgh School of Medicine; U.S. National Cancer Institute of the National Institutes of Health; VGH & UBC Hospital Foundation; Victorian Cancer Agency.